Affimed NV (LTS:0HL9)
$ 6.1 -0.37 (-5.72%) Market Cap: 93.50 Mil Enterprise Value: 35.19 Mil PE Ratio: 0 PB Ratio: 1.46 GF Score: 42/100

Affimed NV Corporate Call Transcript

Dec 10, 2022 / 10:00PM GMT
Alexander Fudukidis
Affimed N.V. - Head of IR

Good afternoon, everyone, and welcome to Affimed's investor event to discuss our announcement today and the development of AFM13, our CD30-positive new lymphoma targeting Innate Cell Engager at the 64th American Society of Hematology Annual Meeting and Exposition. I'm Alex Fudukidis, Head of Investor Relations at Affimed. As a reminder, today's webcast is being recorded and the recording will be made available on our website later today.

Before we begin, I'd like to remind everyone that we issued 2 press releases earlier this afternoon, 1 about our REDIRECT study, the monotherapy study of AFM13 in relapsed refractory PTCL patients and the other about the investigator-sponsored trial of AFM13 in combination with cord blood-derived natural killer cells in CD positive Hodgkin's and non-Hodgkin's lymphoma patients. Both press releases may be found on the Investor Relations section of our website. On our site, you will also find the presentation which we'll be sharing with you today.

Today, we have the following members of our management team

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot